After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Ultragenyx Pharmaceutical Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Ultragenyx Pharmaceutical Inc. is $3.57B. A total of 0.77 million shares were traded on the day, compared to an average of 736.63K shares.
In the most recent transaction, Kassberg Thomas Richard sold 11,509 shares of RARE for 49.93 per share on Mar 11 ’24. After the transaction, the CBO & EVP now owns 252,823 company shares. In a previous transaction on Mar 07 ’24, Fust Matthew K sold 12,195 shares at 50.88 per share. RARE shares that Director owns now total 14,860.
Among the insiders who sold shares, Harris Erik disposed of 4,768 shares on Mar 01 ’24 at a per-share price of $53.76. This resulted in the EVP & Chief Commercial Officer holding 67,163 shares of RARE after the transaction. In another insider transaction, Pinion John Richard sold 4,173 shares at $53.76 per share on Mar 01 ’24. Company shares held by the insider now total 89,268.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, RARE has a high of $54.98 and a low of $31.52.
As of this writing, RARE has an earnings estimate of $Ferrari N.V. per share for the current quarter. EPS was calculated based on a consensus of Dare Bioscience, Inc. estimates, with a high estimate of $Ultragenyx Pharmaceutical Inc. per share and a lower estimate of $Alexandria Real Estate Equities.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. RARE’s latest balance sheet shows that the firm has $740.20M in Cash & Short Term Investments as of fiscal 2021. There were $41.97M in debt and $181.37M in liabilities at the time. Its Book Value Per Share was $3.35, while its Total Shareholder’s Equity was $922.56M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RARE is Buy with a score of 4.80.
